What's new

RSS
Date Content
04/02/2020 Human medicines European public assessment report (EPAR): Xiliarx, vildagliptin, Diabetes Mellitus, Type 2, 19/11/2008, 17, Authorised
04/02/2020 Orphan designation: Recombinant human monoclonal antibody against hepatitis-B virus (active ingredient lenvervimab) for the: Prevention of hepatitis-B re-infection following liver transplantation, 15/08/2013, Positive
03/02/2020 Human medicines European public assessment report (EPAR): Keppra, levetiracetam, Epilepsy, 29/09/2000, 46, Authorised
03/02/2020 News and press releases: EU flags are up in EMA’s new building in Amsterdam
03/02/2020 Orphan designation: Glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine for the: Treatment of maple syrup urine disease, 26/10/2018, Positive
03/02/2020 Orphan designation: Asp-Arg-Val-Tyr-Ile-His-Pro (Angiotensin 1-7) for the: Treatment of epidermolysis bullosa, 20/06/2017, Positive
03/02/2020 Orphan designation: Asp-Arg-Val-Tyr-Ile-His-Pro (Angiotensin 1-7) for the: Treatment of Duchenne muscular dystrophy, 19/02/2014, Positive
03/02/2020 Veterinary medicines European public assessment report (EPAR): Apoquel, oclacitinib maleate, 12/09/2013, 6, Authorised
03/02/2020 Recruitment: European Medicines Agency's privacy statement for selection and recruitment
03/02/2020 Funding
03/02/2020 Financial management and budgetary reporting
03/02/2020 Veterinary medicines European public assessment report (EPAR): Circovac, inactivated porcine circovirus type 2 (PCV2), 21/06/2007, 10, Authorised
03/02/2020 Human medicines European public assessment report (EPAR): VeraSeal, human fibrinogen, human thrombin, Hemostasis, Surgical, 10/11/2017, Additional monitoring, 2, Authorised
03/02/2020 Herbal medicinal product: Taraxaci folium, Taraxaci folium, F: Assessment finalised
03/02/2020 Administration and Corporate Management
01/02/2020 Pharmacovigilance fees: questions and answers
  •